Keywords: blast injury, galantamine, optic nerve, electroretinogram, visual evoked potential, oxidative stress, inflammation, neurotrauma, indirect traumatic optic neuropathy J o u r n a l P r e -p r o o f Journal Pre-proof ABSTRACT Our goal was to investigate the neuroprotective effects of galantamine in a mouse model of blastinduced indirect traumatic optic neuropathy (bITON). Galantamine is an FDA-approved acetylcholinesterase inhibitor used to treat mild-moderate Alzheimer's disease. We exposed one eye of an anesthetized mouse to repeat bursts of over-pressurized air to induce traumatic optic neuropathy. Mice were given regular or galantamine-containing water (120mg/L) ad libitum, beginning immediately after blast and continuing for one month. Electroretinograms and visual evoked potentials were performed just prior to endpoint collection. Histological and biochemical assessments were performed to assess activation of sterile inflammation, axon degeneration, and synaptic changes. Galantamine treatment mitigated visual function deficits induced by our bITON model via preservation of the b-wave of the electroretinogram and the N1 of the visual evoked potential. We also observed a reduction in axon degeneration in the optic nerve as well as decreased rod bipolar cell dendritic retraction. Galantamine also showed anti-inflammatory and antioxidant effects. Galantamine may be a promising treatment for blast-induced indirect traumatic optic neuropathy as well as other optic neuropathies.
INTRODUCTION
Eye injuries affect approximately 2.4 million people every year. 1 Between 2000 and 2010, 186,555 eye injuries occurred worldwide in military hospitals. 2 Further, up to 40% of monocular blindness is due to ocular trauma. 3 Damage to the optic nerve and retina, resulting in permanent visual deficits, occurred in more than 60,000 Veterans with blast-induced traumatic brain injury (TBI) between the years of 2000-2011. 4 Additionally, up to 5% of patients experiencing head trauma will also develop traumatic optic neuropathy (TON). 5, 6 Some of the most common ocular blast injuries include, but are not limited to, hyphema, retinal detachments, retinal edema, TON, and loss of visual field. 7 In cases of direct TON, anatomical disruption of the optic nerve occurs from a projectile penetrating the optic nerve or avulsion. Indirect TON (ITON) results from force transmission to the optic nerve from a distant site without overt damage to the surrounding tissue. 8, 9 Patients with ITON can experience severe vision loss, and while some experience limited recovery, they never return to baseline. 9, 10 Corticosteroids or observation alone are the current standards of treatment for patients with ITON. 11 Our lab has developed a model of blast-induced ITON (bITON), utilizing a repeat blast paradigm in order to simulate repeat injuries most often seen in military populations. 12, 13 This model induces extensive axon degeneration in the optic nerve at two weeks after injury, as well as a decrease in the amplitude and an increase in the latency of the visual evoked potential Western Blot: Single retinas were homogenized and sonicated in lysis buffer and centrifuged.
Sample buffer was added to the supernatant just prior to use. Known amounts of protein (10 to 20 µg) or protein ladder were loaded into each well of an SDS-polyacrylamide gel. The Bio-Rad mini-trans blot cell system and mini protean pre-cast gels at 4-20% were used (Hercules, CA).
Loading control was GAPDH (rabbit; 1:1000; ab9485, Abcam, Cambridge, MA). The protein was transferred onto nitrocellulose using the Bio-Rad trans blot turbo transfer system (Hercules, CA), probed with anti-SOD2 (rabbit; 1:1000; ab13533; Abcam), probed with secondary antibody (alkaline phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG; 1:1000; cat #133466; Jackson ImmunoResearch Laboratories) and alkaline phosphatase was used for band detection.
Band density was quantified by scanning the blot using an EPSON scanner and Adobe
Photoshop to convert to grayscale and invert the image. Each band was selected with the same frame and set measurements were used to obtain the grey mean value for each. 14
High-performance liquid chromatography (HPLC):

Tissue Extraction
The brain sections were homogenized, using a tissue disruptor, in 100-750 ul of 0.1M TCA, which contained 10 -2 M sodium acetate, 10 -4 M EDTA, and 10.5% methanol (pH 3.8). Ten microliters of homogenate was used. Then samples were spun in a microcentrifuge at 10,000g for 20 minutes. The supernatant was removed for biogenic monoamines analysis. 4.60 mm, 2.6um). Biogenic amines were eluted with a mobile phase consisting of 89.5% 0.1M TCA, 10 -2 M sodium acetate, 10 -4 M EDTA and 10.5% methanol (pH 3.8). Solvent was delivered at 0.6 ml/min using a Waters 515 HPLC pump. HPLC control and data acquisition were managed by Empower software. Isoproterenol (5ng/mL) was included in the homogenization buffer for use as a standard to quantify the biogenic amines.
Biogenic Amine Analysis using LC/MS
Biogenic amines were determined in the Vanderbilt University Medical Center Hormone Assay & Analytical Core by a highly sensitive and specific liquid chromatography/mass spectrometry (LC/MS) methodology following derivatization of analytes with benzoyl chloride (BZC). Five microlitersµ of either tissue extract or microdialysis fluid was added to a 1.5mL microcentrifuge tube containing 20 µL acetonitrile. Ten microliters each of 500mM NaCO 3 (aqueous) and 2% BZC in acetonitrile was added to each tube. After 2 min, the reaction was stopped by the addition of 20 µL internal standard solution (in 20% acetonitrile containing 3% sulfuric acid) and 40 µL water. The samples were then ready for LC/MS analysis. LC was performed on a 2.0 x 50mm, 1.7 µm particle Acquity BEH C18 column (Waters Corporation, Milford, MA, USA) using a Waters Acquity UPLC. Mobile phase A was 15% aqueous formic acid and mobile phase B was acetonitrile. Samples were separated by a gradient of 98-5% of mobile phase A over 11 min at a flow rate of 600 µL /min prior to delivery to a SCIEX 6500+ QTrap mass spectrometer.
Protein assay
Protein concentration was determined by BCA Protein Assay Kit (Thermo Scientific). Ten according to previous published protocols 13, 14, 28, 29 . Leica EM-UC7 microtome was used to collect 1 µm-thick sections. Sections were then stained with 1% paraphenylenediamine and 1% toluidine blue and were imaged on a Nikon Eclipse Ni-E microscope using a 100x oil immersion objective (Nikon Instruments Inc., Melville, NY). The optic nerves were montaged into a 5x5 image using the Nikon Elements software. We used the Counting Array and Better Cell Counter plugins to ImageJ, which creates a grid of nine squares overtop the montaged optic nerve. We manually counted healthy and degenerating axons, which are color-coded by the plugins. The grid accounts for 20% of the optic nerve cross-sectional area to avoid bias, and we multiplied these numbers by 5 to estimate total and degenerating axons within the nerve.
were compared to each other using a one-way ANOVA and the Tukey post-hoc test. All groups are shown (mean ± SEM).
RESULTS
Oral galantamine reached bioactive levels in the mouse retina
To determine if galantamine entered the retina and was active, we quantified acetylcholinesterase activity ( Figure 1A ) and acetylcholine levels ( Figure 1B ). Interestingly, control bITON retinas had a slight, but statistically significant increase in acetylcholinesterase activity in comparison to control shams, 0.48 ± 0.03 U/mg (mean ± SEM) and 0.42 ± 0.01 U/mg, respectively (p<0.05; Figure 1A ). Acetylcholinesterase activity was decreased in both galantamine sham (0.28 ± 0.01 U/mg) and galantamine bITON (0.34 ± 0.08 U/mg) groups, as compared to its control, p < 0.001 for both galantamine groups ( Figure 1A) . Interestingly, there is also a statistically significant increase in acetylcholinesterase activity between galantaminesham and galantamine-bITON mice, p<0.05.
The levels of retinal acetylcholine in mice treated with galantamine was greater than controls ( Figure 1B ). Acetylcholine levels were 11.0 ± 1.2, 13.0 ± 3.6; 23.8 ± 10.0, and 30.0 ± 17.2 ng/mg respectively for sham, bITON, galantamine sham, and galantamine-bITON groups ( Figure 1B ). Total choline levels remained unchanged in all four experimental groups ( Figure   1C ).
Previous studies have elucidated that galantamine can modulate glutamate levels. We detected a 2.07-fold increase in glutamate levels in retinas from bITON mice as compared to those from control sham mice (p<0.0001; Figure 1D ). In contrast, levels of glutamate in galantamine-treated mice were similar to control sham levels. To determine if galantamine J o u r n a l P r e -p r o o f modulated glutamate levels by affecting glutamate production or recycling, we performed immunohistochemistry and quantification of fluorescence for a marker of glutamine synthetase (GLAST) and a marker for glutamate transporter 1 (EAAT). No differences in the total fluorescence of either of these markers in the retina were detected (data not shown). We performed immunohistochemical analysis to explore the morphological basis for the ERG b-wave changes. We co-labeled retina cross-sections with anti-PKC, a marker for rod bipolar cells, and anti-synaptophysin, a marker for the photoreceptor ribbon synapse. In control sham mice, the rod bipolar cells extend dendrites up to the photoreceptor terminals ( Figure 2E ).
Galantamine treatment mitigates bITON-induced reduction in the ERG
In contrast, in control bITON mice, the rod bipolar cell dendrites were retracted toward their cell bodies ( Figure 2E) . The rod bipolar cell dendrites of both sham and bITON mice treated with galantamine looked similar to normal sham mouse retinas ( Figure 2E ). In an effort to quantify changes in dendritic overlap with the photoreceptor synaptic terminals, we quantified the extent of double-labeling of the two antibodies. Importantly, galantamine-treated bITON mice had a mean overlap that was comparable to the two sham groups: the mean overlap was 54 ± 2% for galantamine-bITON, sham mice, mean overlap for control-sham was 62 ± 3%, and mean overlap for galantamine-sham mice was 59 ± 3%. There was no statistically significant difference between any of the groups ( Figure 2F ). In contrast, after bITON, mean overlap of anti-PKC and anti-synaptophysin decreased to 41 ± 5% (p<0.05, in comparison to either sham group or galanamine-bITON group).
In order to check the other major synapse at the outer plexiform, we also coimmunolabeled with anti-synaptophysin and anti-calbindin-D, a marker for horizontal cells ( Figure 2G ). There was a marked decrease in calbindin-D immunolabeling after bITON, which prevented visualization of changes in horizontal cell morphology. bITON mice that were treated with galantamine had preserved calbindin labeling. As expected, we quantified a significant difference in overlap in calbindin-D and synaptophysin between sham and bITON mice: sham mean overlap was 59 ± 2% and bITON mean overlap was 42 ± 4%, p<0.05 ( Figure 2H ).
Galantamine preserved the horizontal cell and ribbon synapse double labeling: galantamine sham
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There was no statistical difference between the either of the galantamine groups.
Galantamine treatment mitigated axon degeneration after bITON
Representative micrographs of optic nerve cross-sections from control sham, control bITON, and galantamine-treated bITON mice are shown. Control sham and galantamine-treated bITON nerves exhibit more axons than the control bITON nerve ( Figure 3A -C). Similar to our previous studies, bITON mice had an average of 23,609 ± 1303 axons in the optic nerve with p < 0.0001 in comparison to control shams (52464 ± 4075 axons). 13, 14 Galantamine-treated shams had 52014 ± 2673 axons, and galantamine-treated bITON mice had 48,693 ± 1160 axons ( Figure   3D ), both of which were comparable to the control sham mice.
Galantamine treatment mitigated bITON-induced changes in the VEP
In order to assess transmission of the visual signal to the visual cortex, we performed flash VEPs ( Figure 3E ). Similar to our previously reported findings, the control sham mice had an average VEP N1 amplitude of 42.56 ± 6.78 µV while control bITON mice had an average amplitude of 21.85 ± 11.86 µV, a nearly 2-fold reduction in amplitude (p< 0.0001; Figure 3F ). 14 The control bITON mice also had a longer VEP N1 latency than the control sham mice: 49.34 ± 11.19 ms for bITON as compared to 36.17 ± 7.30 ms (p< 0.0001; Figure 3G ). Regarding the right-shifted latencies of the bITON group, these are due to a deficit in axon conductance, possibly due to changes in energetics or in myelination of the optic nerve.
Galantamine treatment after bITON resulted in partial retention of both the amplitudes and the latencies of the VEP N1 (p<0.001 for amplitudes and p<0.0001 for latencies as compared Figure 3F ). Galantamine sham and bITON mean N1 latencies were 40.38 ± 5.50 ms and 45.75 ± 2.11 ms respectively, with no statistically significant difference between them ( Figure 3G ).
Galantamine mitigated bITON-induced oxidative stress and inflammation
We performed nitrotyrosine immunolabeling and quantified levels of immunofluorescence in order to assess the effect of galantamine on oxidative stress in the retina after bITON ( Figure 4A -F). Nitrotyrosine immunolabeling was nearly absent in control sham retinas ( Figure 4A ). In the control bITON mice, nitrotyrosine immunolabeling was present specifically in the retinal ganglion cell layer ( Figure 4B ). The immunolabeling was significantly reduced in the galantamine-treated bITON retinas ( Figure 4B, D) . To determine which cell type labeled for nitrotyrosine, we co-labeled bITON retinas with the neuronal marker, anti-NeuN. We found that the anti-nitrotyrosine labeling overlapped with the anti-NeuN labeling in the ganglion cell layer ( Figure 4E ). We quantified fluorescence in the retinal ganglion cell layer of all groups ( Figure 4F ). Control bITON mice contained 174 ± 2% more fluorescence than control sham mice, p<0.0001, and 151 ± 5% more fluorescence than galantamine-bITON mice, p<0.0001 ( Figure 4F ). There was no statistically significant difference in fluorescence levels between galantamine sham mice and galantamine-treated bITON mice ( Figure 4F ).
Mitochondrial superoxide dismutase (SOD2) converts the superoxide that is formed as a metabolic by-product of oxidative phosphorylation into oxygen and thus is a critical enzyme in regulating intracellular ROS levels. Similar to our previously studies, we detected a 59 ± 4% J o u r n a l P r e -p r o o f decrease in SOD2 levels at one month after control bITON as compared to control shams ( Figure   4G ). 14 In contrast, SOD2 levels in galantamine-treated sham and bITON mice were comparable to control shams. We detected a statistically significant difference (p<0.001) between either galantamine-treated group and the control bITON group ( Figure 4G) .
We detected an increase in the pro-inflammatory cytokines, IL-1α and IL-1β in the control bITON retinas, in agreement with our previous findings ( Figure 4H ). 14 pg/ml, compared to 4.1 ± 1.9 pg/ml detected in control sham retinas (p<0.001) ( Figure 4I ). In contrast, galantamine-treated sham retinas and galantamine-treated bITON retinas contained similar levels of IL-1β: 2.7 ± 1.7 pg/ml and 2.8 ± 1.4 pg/ml, respectively and were not significantly different from control sham retinas.
DISCUSSION
In this study, we initiated treatment of galantamine after the last of a 3-day series of blast exposures. We previously demonstrated that our bITON model induces axon degeneration after only three blasts, which suggests that injury responses started prior to the last day of the blasts and the start of galantamine treatment. 15 We show that oral galantamine given ad libitum reached the retina, where it increased acetylcholine levels and decreased acetylcholinesterase activity.
This treatment paradigm mitigated bITON-induced visual function deficits, axon degeneration in J o u r n a l P r e -p r o o f the optic nerve and rod bipolar cell dendritic retraction. Further, it moderated oxidative stress, inflammation, and glutamate levels.
After bITON, rod bipolar cells were present, but their dendrites were retracted toward their cell bodies (Figure 2E ). This correlates with the decrease in the b-wave amplitude (Figure   2A , C) and increase in the b-wave latency detected after bITON (Figure 2A, D) . Coimmunolabeling of nitrotyrosine and NeuN in the ganglion cell layer demonstrates that the cells primarily affected by bITON-induced oxidative stress are retinal ganglion cells and possibly displaced amacrine cells ( Figure 4E ). This is consistent with our previously study showing loss of cells in the ganglion cell layer. 15 We have performed TUNEL and do not detect active cell death in the retina at the post-bITON time-points we have examined (data not shown). In contrast, based on the ERG, OCT thickness (data not shown), and immunolabeling results, bITON does not cause significant loss of bipolar or amacrine cells. We do not detect a difference in overall retinal thickness or in the thickness of any particular layer of the retina by OCT (data not shown). In addition, the a-wave and the oscillatory potentials of the ERG are unaltered in our bITON model suggesting that the photoreceptors and AII amacrine cells are unaffected (data not shown). Thus, while we cannot discount some loss of other retinal neurons, it is likely minimal.
In contrast, the right-shifted latencies of the VEP of the bITON group ( Figure 3G ) suggest a deficit in axon conductance, possibly due to changes in axon energetics or myelination in the optic nerve, which again points to dysfunction of the RGCs and matches the optic nerve histological findings reported here and elsewhere. 14, 15 In most cases, galantamine treatment resulted in partial protection of the retina. Treating earlier after injury may be more effective. There also may be injury pathways activated by bITON that are unaffected by galantamine. Further studies are needed to determine how long J o u r n a l P r e -p r o o f Journal Pre-proof after injury galantamine treatment can be initiated and still be effective. Additionally, the decreases in oxidative stress and inflammation in galantamine-treated retinas may be an indirect result of galantamine action that prevents secondary axon degeneration and cell injury as opposed to a direct action on these pathways.
Detection of elevated glutamate in post-bITON retinas is consistent with reports in other models of TBI or blast injury. In a rat TBI study, there was a nine-fold increase in extracellular glutamate levels in the brain as compared to control animals. 32 In a model of rat blast injury, glutamate was significantly increased in the retina. 33 Additionally, many preclinical and clinical studies have demonstrated altered glutamate production, clearance, and buffering after TBI that results in an excess of glutamate. 32, 34 It possible that glutamate may play a large role in determining the state of the post-injury CNS. Glutamate is the most abundant excitatory neurotransmitter within the CNS and excess glutamate can lead to a massive increase in neuronal activity, increased intracellular calcium, and even cell death, i.e. excitotoxicity. Retinal astrocytes and Müller glia play an important role in glutamate buffering and clearance. Knockout of the glial protein, EAAT1, in mice exposed to TBI exhibit excitotoxic levels of glutamate in comparison to controls. 35 Additionally, TBI in rats results in excess glutamate followed by a downregulation in expression of GLAST and EAAT1 in glial cells. 36 However, in this study, we did not find a difference in the immunohistochemical labeling of GLAST or EAAT1 between any of our groups, despite the observed increases in retinal glutamate following bITON.
Galantamine has been shown to act as a modulator of glutamate-induced excitotoxicity by preventing increases in cell death following exposure to NMDA. 21 It is feasible that galantamine acted upstream to the mechanism that caused an increase in glutamate. This should be explored in future studies.
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The positive effect of galantamine on oxidative stress and inflammation in our bITON model are in agreement with other reports showing that galantamine has antioxidant and antiinflammatory effects on cells both in culture and in vivo. 23, 24 Galantamine treatment reduced IL-1 levels in the brain of a hypoxia-ischemic rat model, and protected cortical neurons following injury. 36 Additionally, galantamine decreased oxidative stress and apoptosis in cortical neurons exposed to amyloid-beta peptides and in neuroblastoma cells that were treated with hydrogen peroxide. 22, 24 Galantamine has been utilized in a variety of neurodegenerative disease models other than Alzheimer's, and has demonstrated protection. Galantamine treatment, via modulation of the muscarinic acetylcholine receptors in the retina, has shown to be protective in multiple models of glaucoma by promoting retinal ganglion cell survival. 27, 38 Additionally, through its inhibition of acetylcholinesterase, galantamine treatment was protective in another model of glaucoma via increasing blood flow. 26 Outside the retina, efferent vagus nerve activity, via the cholinergic anti-inflammatory pathway, is responsible for regulation of cytokine production via α7nAChR-dependent signaling. 39 Galantamine is a positive allosteric modulator of α7nAChRs, so it is feasible that the protection we detected was due to activation of this anti-inflammatory pathway. 21, 40, 41 Overall, our results are comparable with previous studies showing that galantamine has antioxidant and anti-inflammatory effects and is neuroprotective. 
